BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14998856)

  • 1. Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone.
    Gamberi G; Benassi MS; Ragazzini P; Pazzaglia L; Ponticelli F; Ferrari C; Balladelli A; Mercuri M; Gigli M; Bertoni F; Picci P
    Ann Oncol; 2004 Mar; 15(3):498-503. PubMed ID: 14998856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of markers of possible prognostic value in 57 giant cell tumors of bone.
    Gamberi G; Serra M; Ragazzini P; Magagnoli G; Pazzaglia L; Ponticelli F; Ferrari C; Zanasi M; Bertoni F; Picci P; Benassi MS
    Oncol Rep; 2003; 10(2):351-6. PubMed ID: 12579271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
    Zheng MH; Fan Y; Panicker A; Smith A; Robertson T; Wysocki S; Robbins P; Papadimitriou JM; Wood DJ
    Am J Pathol; 1995 Dec; 147(6):1559-66. PubMed ID: 7495280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone].
    Li H; Dong S; Zeng Y
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):386-8. PubMed ID: 11810768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-1beta regulates urokinase plasminogen activator (u-PA), u-PA receptor, soluble u-PA receptor, and plasminogen activator inhibitor-1 messenger ribonucleic acid expression in cultured human endometrial stromal cells.
    Chung HW; Wen Y; Ahn JJ; Moon HS; Polan ML
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1332-40. PubMed ID: 11238529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
    Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell invasion is affected by differential expression of the urokinase plasminogen activator/urokinase plasminogen activator receptor system in muscle satellite cells from normal and dystrophic patients.
    Fibbi G; Barletta E; Dini G; Del Rosso A; Pucci M; Cerletti M; Del Rosso M
    Lab Invest; 2001 Jan; 81(1):27-39. PubMed ID: 11204271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
    Huang L; Xu J; Wood DJ; Zheng MH
    Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
    Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
    Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone.
    Si AI; Huang L; Xu J; Kumta SM; Wood D; Zheng MH
    J Cell Biochem; 2003 Aug; 89(6):1154-63. PubMed ID: 12898514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
    Bryan L; Paugh BS; Kapitonov D; Wilczynska KM; Alvarez SM; Singh SK; Milstien S; Spiegel S; Kordula T
    Mol Cancer Res; 2008 Sep; 6(9):1469-77. PubMed ID: 18819934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
    Benassi MS; Ponticelli F; Azzoni E; Gamberi G; Pazzaglia L; Chiechi A; Conti A; Spessotto P; Scapolan M; Pignotti E; Bacchini P; Picci P
    Histol Histopathol; 2007 Sep; 22(9):1017-24. PubMed ID: 17523079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.
    Yoshino H; Endo Y; Watanabe Y; Sasaki T
    Br J Cancer; 1998 Sep; 78(6):833-9. PubMed ID: 9743310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
    Shiomi H; Eguchi Y; Tani T; Kodama M; Hattori T
    Am J Pathol; 2000 Feb; 156(2):567-75. PubMed ID: 10666386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
    Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
    Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR.
    Guenther R; Krenn V; Morawietz L; Dankof A; Melcher I; Schaser KD; Kasper HU; Kuban RJ; Ungethüm U; Sers C
    Pathol Res Pract; 2005; 201(10):649-63. PubMed ID: 16325507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
    Smit JW; van der Pluijm G; Romijn HA; Löwik CW; Morreau H; Goslings BM
    Thyroid; 1999 Sep; 9(9):913-9. PubMed ID: 10524570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
    McGarvey TW; Kariko K; Barnathan ES; Thomas J; Malkowicz SB
    Int J Oncol; 1998 Jan; 12(1):175-80. PubMed ID: 9454902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.